BRL 3
Alternative Names: BRL3Latest Information Update: 19 Mar 2007
At a glance
- Originator Barr Laboratories
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Mar 2007 Discontinued - Phase-III for Cancer in USA (unspecified route)
- 22 Aug 2001 Phase-III clinical trials for Cancer in USA (Unknown route)